Evogliptin (tartrate)
Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation[1][2][3][4].
Product Specifications
CAS Number
1222102-51-3
Product Name Alternative
DA-1229 (tartrate)
UNSPSC
12352005
Target
Autophagy; Dipeptidyl Peptidase
Type
Reference compound
Related Pathways
Autophagy; Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/evogliptin-tartrate.html
Purity
99.71
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1NCCN(C(C[C@H](N)CC2=CC(F)=C(F)C=C2F)=O)[C@@H]1COC(C)(C)C.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Molecular Formula
C23H32F3N3O9
Molecular Weight
551.51
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 4
Isoform
DPP-4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD50 (ICAM-3) (186-2G9), CF740 conjugate, 0.1mg/mL
Von Willebrand Factor (3E2D10), CF405S conjugate, 0.1mg/mL
